<p>(A) Schematic of assay plate map used in screening the chemical compound library. (B) Reproducibility of raw data between duplicate assay plates for control wells containing IFN-β (0–200 U/ml) and test wells containing compound plus IFN-β (5 U/ml). Dashed lines indicate median ± SD of each data set from the test wells. (C) Signal consistency through a full screen of 56 assay plates. Values represent replicate A of assay plate 1 (the first plate) and plate 55 (the last plate). Box plots represent median and 25<sup>th</sup> and 75<sup>th</sup> percentile, and whiskers indicate minimum and maximum of data. Arrows indicate values from test wells.</p
<p>A. Composite heat map of 99 384-well plates used for the pilot screen using the full complement o...
<p>A, <i>left panel</i>. Representative image of realtime monitoring of Ca<sup>2+</sup>-mobilization...
<p>Plot of percent inhibition for duplicate screen of the 1280 LOPAC compounds. LOPAC compounds (blu...
: Pilot testing of an assay intended for high-throughput screening (HTS) with small compound sets is...
<p>The HTS assay begins with manual preparation of working solutions of pH-MM<sup>Suc</sup> and a ba...
Pilot testing of an assay intended for high-throughput screening (HTS) is a necessary but often time...
<p>Raw fluorescence data from the Spectrum screen were normalized to the assay controls on each plat...
For each compound (dots), the relative GFP fluorescence of the screening target in the primary scree...
<p>(A) Plate layout for screening BSH inhibitors. Pink boxes (columns 3–22) indicate test wells that...
<p>TOP: scattergram of percent inhibition data from all plates in the Genzyme HTS. Green: 100% inhib...
<p>(<b>A.</b>) Percent activity scatterplot for all bioactive compounds screened at single point (12...
<p><b>A.</b> Correlation of corresponding wells from duplicate plates in the library. Wells with few...
<p>A flow diagram of various assays used in the screen. The number of hits remaining after each run ...
Despite a large body of references on assay development, assay optimization, strategies, and methodo...
<p>Of fifteen compounds surviving dose-response potency testing, five commercially-available molecul...
<p>A. Composite heat map of 99 384-well plates used for the pilot screen using the full complement o...
<p>A, <i>left panel</i>. Representative image of realtime monitoring of Ca<sup>2+</sup>-mobilization...
<p>Plot of percent inhibition for duplicate screen of the 1280 LOPAC compounds. LOPAC compounds (blu...
: Pilot testing of an assay intended for high-throughput screening (HTS) with small compound sets is...
<p>The HTS assay begins with manual preparation of working solutions of pH-MM<sup>Suc</sup> and a ba...
Pilot testing of an assay intended for high-throughput screening (HTS) is a necessary but often time...
<p>Raw fluorescence data from the Spectrum screen were normalized to the assay controls on each plat...
For each compound (dots), the relative GFP fluorescence of the screening target in the primary scree...
<p>(A) Plate layout for screening BSH inhibitors. Pink boxes (columns 3–22) indicate test wells that...
<p>TOP: scattergram of percent inhibition data from all plates in the Genzyme HTS. Green: 100% inhib...
<p>(<b>A.</b>) Percent activity scatterplot for all bioactive compounds screened at single point (12...
<p><b>A.</b> Correlation of corresponding wells from duplicate plates in the library. Wells with few...
<p>A flow diagram of various assays used in the screen. The number of hits remaining after each run ...
Despite a large body of references on assay development, assay optimization, strategies, and methodo...
<p>Of fifteen compounds surviving dose-response potency testing, five commercially-available molecul...
<p>A. Composite heat map of 99 384-well plates used for the pilot screen using the full complement o...
<p>A, <i>left panel</i>. Representative image of realtime monitoring of Ca<sup>2+</sup>-mobilization...
<p>Plot of percent inhibition for duplicate screen of the 1280 LOPAC compounds. LOPAC compounds (blu...